142 related articles for article (PubMed ID: 19759108)
1. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.
Pillarsetty N; Punzalan B; Larson SM
J Nucl Med; 2009 Oct; 50(10):1709-14. PubMed ID: 19759108
[TBL] [Abstract][Full Text] [Related]
2. Validation of R-2-[
Zhang Z; Liu S; Ma H; Nie D; Wen F; Zhao J; Sun A; Yuan G; Su S; Xiang X; Hu P; Tang G
Mol Imaging Biol; 2019 Dec; 21(6):1127-1137. PubMed ID: 30847820
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate.
Ponde DE; Dence CS; Oyama N; Kim J; Tai YC; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2007 Mar; 48(3):420-8. PubMed ID: 17332620
[TBL] [Abstract][Full Text] [Related]
4. Propionic Acid-Based PET Imaging of Prostate Cancer.
Zhang Z; Liu S; Ma H; Xiang X; Nie D; Hu P; Tang G
Mol Imaging Biol; 2021 Dec; 23(6):836-845. PubMed ID: 33876336
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
Zhang L; Yao X; Cao J; Hong H; Zhang A; Zhao R; Zhang Y; Zha Z; Liu Y; Qiao J; Zhu L; Kung HF
Mol Pharm; 2019 Mar; 16(3):1156-1166. PubMed ID: 30676751
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
7. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer.
Kwan KH; Burvenich IJG; Centenera MM; Goh YW; Rigopoulos A; Dehairs J; Swinnen JV; Raj GV; Hoy AJ; Butler LM; Scott AM; White JM; Ackermann U
Nucl Med Biol; 2021 Feb; 93():37-45. PubMed ID: 33310350
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Antilipolytic drug boosts glucose metabolism in prostate cancer.
Andersen KF; Divilov V; Koziorowski J; Pillarsetty N; Lewis JS
Nucl Med Biol; 2013 May; 40(4):524-8. PubMed ID: 23454248
[TBL] [Abstract][Full Text] [Related]
11. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
12. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.
Zhang K; Aruva MR; Shanthly N; Cardi CA; Rattan S; Patel C; Kim C; McCue PA; Wickstrom E; Thakur ML
J Nucl Med; 2008 Jan; 49(1):112-21. PubMed ID: 18077536
[TBL] [Abstract][Full Text] [Related]
14. PET Imaging of Hepatocellular Carcinomas:
Zhao J; Zhang Z; Nie D; Ma H; Yuan G; Su S; Liu S; Liu S; Tang G
Mol Imaging; 2019; 18():1536012118821032. PubMed ID: 30799682
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three ¹⁸F-labeled carboxylic acids with ¹⁸F-FDG of the differentiation tumor from inflammation in model mice.
Wang H; Tang G; Hu K; Huang T; Liang X; Wu Z; Li S
BMC Med Imaging; 2016 Jan; 16():2. PubMed ID: 26754531
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
19. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
20. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model.
Oyama N; Kim J; Jones LA; Mercer NM; Engelbach JA; Sharp TL; Welch MJ
Nucl Med Biol; 2002 Nov; 29(8):783-90. PubMed ID: 12453586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
